In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Timothy Wiltshire, Ph.D., assistant professor of laboratory medicine and pathology in the Division of Transfusion Medicine, to discuss what’s new with CAR-T cells.
Timestamps:
0:00 Introduction
0:49 Why is CAR-T important for healthcare folks to appreciate in 2023?
3:05 What should healthcare professionals understand about CAR-T?
4:55 Is it true to say that we’ve seen success specifically in the hematologic cancers like leukemias, but not necessarily like the solid tumors, like breast cancer or prostate cancer?
7:27 Are there a few things that you look for when you read an article that’s reporting about CAR-T cells?
10:24 Can you explain what off-target effects are?
11:46 What are some of the new things that have come out recently?
13:24 What’s involved with creating your typical CAR-T?
14:58 What are your thoughts on the future for the field?
16:22 Is this a more equitable product or are there still some struggles with getting equity for different populations with CAR-T?
17:25 Is the promise of an off-the-shelf not just for an emergency, but could that be a cheaper option?
18:00 Outro